Because of the scale and risk of international transmission, the WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) in May 2026.

Why Existing Ebola Vaccines Don’t Directly Apply

The main challenge is that the virus responsible for this outbreak is Bundibugyo ebolavirus, not the Zaire ebolavirus responsible for several recent outbreaks in West and Central Africa.

Current licensed vaccines and treatments—including Merck’s Ervebo—were developed specifically to target the Zaire strain of Ebola, not Bundibugyo. As a result, regulators note that no authorized vaccines or specific treatments currently exist for Bundibugyo virus disease.

That mismatch means the vaccines that helped control past outbreaks cannot automatically be assumed to work here.

Why Ervebo Is Still Being Considered

Despite the mismatch, Ervebo remains the most obvious candidate for emergency use. The vaccine has been widely deployed in previous Ebola outbreaks using ring‑vaccination strategies, in which contacts of confirmed cases and frontline health workers are vaccinated to block further transmission.

Researchers are considering whether the immune response triggered by Ervebo could provide some level of cross‑protection against Bundibugyo ebolavirus. Evidence for this possibility is limited, but a small amount of scientific data suggests it might offer partial protection even though it targets a different Ebola species.

That uncertainty is exactly why the WHO panel is meeting—to evaluate whether the potential benefits outweigh the risks of deploying a vaccine not designed for the circulating virus.

The Core Risk–Benefit Question

The experts’ decision essentially comes down to a difficult trade‑off.

On one side:

• The Bundibugyo strain has historically produced case‑fatality rates between roughly 30% and 50% in past outbreaks.
• There is no approved vaccine or therapeutic treatment available specifically for this virus.

On the other side:

• The effectiveness of Ervebo against Bundibugyo in humans has not been demonstrated.
• Deploying it would mean using the vaccine outside the indication for which it was developed and licensed.

Public‑health officials therefore must decide whether an imperfect or uncertain tool could still reduce infections, severe illness, or deaths, especially among healthcare workers and close contacts of cases.

If Used, It Would Likely Be an Emergency Deployment

Any use of Ervebo against Bundibugyo would almost certainly occur under emergency or off‑label authorization, rather than as a standard vaccination campaign. That approach would involve coordination between WHO, national regulators, and the governments of affected countries.

Such a deployment would also require strong monitoring systems. Authorities would need to track:

• who receives the vaccine
• exposure levels among vaccinated individuals
• infections and outcomes after vaccination
• potential adverse events

Collecting this information would be crucial for understanding whether the vaccine actually helps against Bundibugyo and for guiding future outbreak responses.

A Decision Under Uncertainty

The WHO advisory discussion reflects a broader reality of outbreak response: sometimes scientists must act before perfect evidence exists. With hundreds of cases and deaths already reported and no targeted vaccine available, the question is whether using an existing Ebola vaccine with uncertain effectiveness is better than having no vaccine option at all.

The expert panel’s deliberations are aimed at answering that question while balancing scientific caution with the urgent need to contain a dangerous epidemic.

Because of the scale and risk of international transmission, the WHO declared the outbreak a Public Health Emergency of International Concern (PHEIC) in May 2026.

Why Existing Ebola Vaccines Don’t Directly Apply

The main challenge is that the virus responsible for this outbreak is Bundibugyo ebolavirus, not the Zaire ebolavirus responsible for several recent outbreaks in West and Central Africa.

Current licensed vaccines and treatments—including Merck’s Ervebo—were developed specifically to target the Zaire strain of Ebola, not Bundibugyo. As a result, regulators note that no authorized vaccines or specific treatments currently exist for Bundibugyo virus disease.

That mismatch means the vaccines that helped control past outbreaks cannot automatically be assumed to work here.

Why Ervebo Is Still Being Considered

Despite the mismatch, Ervebo remains the most obvious candidate for emergency use. The vaccine has been widely deployed in previous Ebola outbreaks using ring‑vaccination strategies, in which contacts of confirmed cases and frontline health workers are vaccinated to block further transmission.

Researchers are considering whether the immune response triggered by Ervebo could provide some level of cross‑protection against Bundibugyo ebolavirus. Evidence for this possibility is limited, but a small amount of scientific data suggests it might offer partial protection even though it targets a different Ebola species.

That uncertainty is exactly why the WHO panel is meeting—to evaluate whether the potential benefits outweigh the risks of deploying a vaccine not designed for the circulating virus.

The Core Risk–Benefit Question

The experts’ decision essentially comes down to a difficult trade‑off.

On one side:

• The Bundibugyo strain has historically produced case‑fatality rates between roughly 30% and 50% in past outbreaks.
• There is no approved vaccine or therapeutic treatment available specifically for this virus.

On the other side:

• The effectiveness of Ervebo against Bundibugyo in humans has not been demonstrated.
• Deploying it would mean using the vaccine outside the indication for which it was developed and licensed.

Public‑health officials therefore must decide whether an imperfect or uncertain tool could still reduce infections, severe illness, or deaths, especially among healthcare workers and close contacts of cases.

If Used, It Would Likely Be an Emergency Deployment

Any use of Ervebo against Bundibugyo would almost certainly occur under emergency or off‑label authorization, rather than as a standard vaccination campaign. That approach would involve coordination between WHO, national regulators, and the governments of affected countries.

Such a deployment would also require strong monitoring systems. Authorities would need to track:

• who receives the vaccine
• exposure levels among vaccinated individuals
• infections and outcomes after vaccination
• potential adverse events

Collecting this information would be crucial for understanding whether the vaccine actually helps against Bundibugyo and for guiding future outbreak responses.

A Decision Under Uncertainty

The WHO advisory discussion reflects a broader reality of outbreak response: sometimes scientists must act before perfect evidence exists. With hundreds of cases and deaths already reported and no targeted vaccine available, the question is whether using an existing Ebola vaccine with uncertain effectiveness is better than having no vaccine option at all.

The expert panel’s deliberations are aimed at answering that question while balancing scientific caution with the urgent need to contain a dangerous epidemic.